09.11.20: Not intended for U.S. and UK Media

Bayer submits marketing authorization applications for finerenone in the U.S. and the EU for patients with chronic kidney disease and type 2 diabetesRegulatory submissions based on positive data from Phase III FIDELIO-DKD study recently published in the New England Journal of Medicinemehr ...
Source: Bayer IR Newsfeed: Events - Category: Pharmaceuticals Source Type: news